{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:45:39Z","timestamp":1793677539752,"version":"4.5.1"},"reference-count":15,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["T35DK104689"],"award-info":[{"award-number":["T35DK104689"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014848","name":"Arnold Ventures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation"},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program"},{"name":"Stravros Niarchos Foundation"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Policy and Practice"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/20523211.2025.2564405","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T08:47:16Z","timestamp":1759308436000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic benefit of the most expensive drugs covered by Medicare and Medicaid"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1943-0962","authenticated-orcid":false,"given":"Tiffany Enxia","family":"Jiang","sequence":"first","affiliation":[{"name":"Yale School of Medicine","place":["New Haven, USA"]},{"name":"Yale School of Medicine","place":["New Haven, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3845-3606","authenticated-orcid":false,"given":"Reshma","family":"Ramachandran","sequence":"additional","affiliation":[{"name":"Yale School of Medicine","place":["New Haven, USA"]},{"name":"Yale School of Medicine","place":["New Haven, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6997-7384","authenticated-orcid":false,"given":"Kerstin N.","family":"Vokinger","sequence":"additional","affiliation":[{"name":"University of Zurich","place":["Zurich, Switzerland"]},{"name":"ETH Zurich","place":["Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9218-3320","authenticated-orcid":false,"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Yale School of Medicine","place":["New Haven, USA"]},{"name":"Yale School of Medicine","place":["New Haven, USA"]},{"name":"Yale School of Public Health","place":["New Haven, USA"]},{"name":"Yale-New Haven Health System","place":["New Haven, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,10]]},"reference":[{"key":"e_1_3_6_2_1","unstructured":"Comparing Prescription Drugs in the U.S. and Other Countries: Prices and Availability. (2024 January 31). ASPE. https:\/\/aspe.hhs.gov\/reports\/comparing-prescription-drugs."},{"key":"e_1_3_6_3_1","unstructured":"Cubanski J. (2025 January 23). FAQs about the Inflation Reduction Act\u2019s Medicare Drug Price Negotiation Program. KFF. https:\/\/www.kff.org\/other\/issue-brief\/faqs-about-the-inflation-reduction-acts-medicare-drug-price-negotiation-program\/."},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.4034"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1855"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3434"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2012.0541"},{"issue":"2","key":"e_1_3_6_8_1","first-page":"65","article-title":"How safe and innovative are first-in-class drugs approved by health Canada: A cohort study","volume":"12","author":"Lexchin J.","year":"2016","unstructured":"Lexchin, J. (2016). How safe and innovative are first-in-class drugs approved by health Canada: A cohort study. Healthcare Policy, 12(2), 65\u201375.","journal-title":"Healthcare Policy"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-024-08651-8"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.35064"},{"key":"e_1_3_6_11_1","unstructured":"Medicare Drug Price Negotiation | CMS. (2025). https:\/\/www.cms.gov\/inflation-reduction-act-and-medicare\/medicare-drug-price-negotiation."},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.22.4.220"},{"key":"e_1_3_6_13_1","unstructured":"Seshamani M. (2024 October 2). Medicare drug price negotiation program: Final guidance implementation of sections 1191\u20131198 of the social security act for initial price applicability year 2027 and manufacturer effectuation of the maximum fair price in 2026 and 2027. https:\/\/www.cms.gov\/files\/document\/medicare-drug-price-negotiation-final-guidance-ipay-2027-and-manufacturer-effectuation-mfp-2026-2027.pdf."},{"key":"e_1_3_6_14_1","unstructured":"Sparks G. Kirzinger A. Montero A. Valdes I. & Published L. H. (2024 October 4). Public opinion on prescription drugs and their prices. KFF. https:\/\/www.kff.org\/other\/poll-finding\/public-opinion-on-prescription-drugs-and-their-prices\/."},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30139-X"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.2685"}],"container-title":["Journal of Pharmaceutical Policy and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/20523211.2025.2564405","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T13:17:20Z","timestamp":1765891040000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/20523211.2025.2564405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/20523211.2025.2564405"],"URL":"https:\/\/doi.org\/10.1080\/20523211.2025.2564405","relation":{},"ISSN":["2052-3211"],"issn-type":[{"value":"2052-3211","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=jppp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=jppp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-03-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2564405"}}